Abstract:Respiratory syncytial virus (RSV) is a major cause of lower respiratory tract infection (LRTI), hospitalization, and mortality in infants and young children globally. The greatest burden of severe disease and mortality occurs in low‐middle income countries (LMICs), with large and vulnerable childhood populations. The highest rates of RSV‐hospitalization occur in healthy‐term infants under 3 months of age. Preterm infants, children with chronic lung disease of prematurity, Down's syndrome, congenital heart disease, or immunodeficiency also have a higher risk of severe RSV‐LRTI. Early‐life RSV‐LRTI has also been associated with chronic sequelae, including recurrent LRTI, recurrent wheezing, asthma, and lung function impairment. A RSV pre‐fusion (F) maternal vaccine and long‐acting monoclonal antibody (nirsevimab) have been licensed for the prevention of RSV‐LRTI in infants and young children. Studies show high efficacy and effectiveness particularly for preventing severe RSV‐LRTI. Maternal RSV vaccine given at 24–36 weeks of pregnancy was effective in preventing RSV medically attended LRTI and severe RSV‐LRTI through 6 months after birth in a phase 3 study conducted in 18 countries over two RSV seasons. Vaccination was safe with no significant difference in adverse events between infants born to mothers who received RSV preF vaccine compared to placebo. A numerical imbalance in preterm births that occurred predominantly in South Africa, unrelated to vaccine timing or gestational age at vaccination and unassociated with mortality, coincided with COVID‐19 delta and omicron waves. Nirsevimab, given as a single dose prior or during the RSV season, had high efficacy in preventing RSV‐LRTI hospitalization in infants in preterm and in full‐term infants, as well as in young children with underlying conditions through 150 days post administration in phase 2 and 3 trials. High effectiveness against hospitalization or severe disease in infants and in at‐risk children up to 2 years of age has also been reported in several countries where implementation has occurred. RSV‐LRTI is now a preventable disease in infants and young children. Rapid implementation of these highly effective interventions has occurred in many high‐income countries, but access remains very limited in LMICs. Access to such RSV preventive interventions is urgently needed for all children to strengthen child health and promote global equity.

RSV, Antibodies and the Developing World

Antibody-mediated protection against respiratory syncytial virus in children

Respiratory syncytial virus vaccination and immunoprophylaxis: realising the potential for protection of young children

Maternal RSV vaccine development. Where to from here?

Respiratory syncytial virus (RSV): a scourge from infancy to old age

Current State and Challenges in Developing Respiratory Syncytial Virus Vaccines

Expert Consensus on the Diagnosis, Treatment, and Prevention of Respiratory Syncytial Virus Infections in Children

New advances in RSV: Is prevention attainable?

Severe respiratory syncytial virus infection in children: burden, management, and emerging therapies

The respiratory syncytial virus vaccine and monoclonal antibody landscape: the road to global access

Immunity to RSV in Early-Life

Current concepts and progress in RSV vaccine development

An Overview of Respiratory Syncytial Virus Vaccine Development

Respiratory Syncytial Virus: Infection, Detection, and New Options for Prevention and Treatment

Challenges in the prevention or treatment of RSV with emerging new agents in children from low- and middle-income countries

Respiratory syncytial virus: diagnosis, prevention and management

Current State of Respiratory Syncytial Virus Disease and Management

Research Progress in Respiratory Syncytial Virus Vaccines

The RSV roadmap in children: Lessons learned, paths forward

Passive Immunization Strategies to Prevent Severe Respiratory Syncytial Virus Infection Among Newborns and Young Infants

Correlates of Protection Against Respiratory Syncytial Virus Infection in Infancy